New Multifunctional Platinum (IV) Complexes Incorporating Cannabidiol Active Moieties Elicit Mitochondrial Damage and Synergistically Boost Antitumor Efficacy

This study focuses on the synthetic modification of satraplatin through axial position substitution by introducing the bioactive molecule cannabidiol (CBD) at the axial position, leading to novel multifunctional antitumor complexes S1–S5. The results demonstrate that the target complexes exhibit significantly optimized physicochemical properties with improved lipo–hydro partition coefficients, combining both lipophilic and hydrophilic characteristics that favor drug metabolism. Remarkably enhanced in vitro antitumor activity was observed: S3 showed 4.3‐fold higher cytotoxicity than satraplatin in HCT‐116 cells, with superior efficacy against drug‐resistant cells. S5 demonstrated 22‐fold greater antiproliferative activity than both parental satraplatin and CBD alone in A549 cells, likely attributable to its haloacetic axial group enhancing mitochondrial targeting for trifunctional synergistic antitumor effects. Mechanistic studies revealed that the complexes are reduced by ascorbic acid in vivo to release both CBD and Pt (II). CBD disrupts redox homeostasis through ROS accumulation and impairs mitochondrial membrane potential, synergizing with Pt (II)‐induced DNA damage to promote cancer cell apoptosis. The introduction of bioactive moieties like CBD with excellent biological functions into the axial position of Pt (IV) complexes not only optimizes physicochemical properties but also enriches antitumor functionality. Compared with conventional platinum drugs, these complexes demonstrate significantly enhanced cytotoxicity (S3 is 9.5‐fold more toxic than cisplatin in HCT‐116 cells; S5 shows 33‐fold higher antiproliferative activity in A549 cells) while maintaining superior activity against resistant cells through CBD‐Pt (II) synergy. This study provides valuable insights for overcoming limitations of traditional platinum drugs and developing synergistic antitumor agents with enhanced efficacy.

• Publication year

  2025

• Venue

  Applied organometallic chemistry

• Publication date

  2025-10-02

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1002/aoc.70416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Pt(IV) complex OAP2 induces STING activation and pyroptosis via mitochondrial membrane remodeling for synergistic chemo-immunotherapy

  2023cited by this paper
• Ovarian Cancer—Insights into Platinum Resistance and Overcoming It

  2023cited by this paper
• Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges

  2022cited by this paper
• Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?

  2021cited by this paper
• Mitochondrial Voltage-Dependent Anion Channel 1-Hexokinase-II Complex-Targeted Strategy for Melanoma Inhibition Using Designed Multiblock Peptide Amphiphiles.

  2021cited by this paper
• Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance

  2020cited by this paper
• Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83

  2020cited by this paper
• Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy

  2020cited by this paper
• Synthesis and Cytotoxicity of Water-Soluble Dual- and Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates.

  2019cited by this paper
• Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

  2019cited by this paper
• Current Status for Oral Platinum (IV) Anticancer Drug Development

  2018cited by this paper
• Apoptosis by [Pt(O,O′-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma

  2017cited by this paper
• Cannabidiol: State of the art and new challenges for therapeutic applications.

  2017cited by this paper
• Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position

  2016cited by this paper
• The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

  2016cited by this paper
• Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery

  2014cited by this paper
• Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

  2012cited by this paper
• Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation.

  2012cited by this paper
• Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations.

  2012cited by this paper
• A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells.

  2011cited by this paper
• Anticancer Activity of Metal Complexes: Involvement of Redox Processes

  2011cited by this paper
• Lipophilicity in drug discovery

  2010cited by this paper
• Interaction between platinum complexes and a methionine motif found in copper transport proteins.

  2007cited by this paper
• Reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by aqueous extracts of cancer cells.

  2007cited by this paper

• No citing papers are available for this paper.